多糖铁复合物胶囊治疗孕中晚期缺铁性贫血患者的效果

Effect of Iron Polysaccharide Complex Capsules in the Treatment of Patients with Iron Deficiency Anemia in Middle and Late Pregnancy

目的:探讨多糖铁复合物胶囊治疗孕中晚期缺铁性贫血患者的效果。方法:选取2021年10月—2022年6月选择建档并分娩的中晚期缺铁性贫血产妇108例作为研究对象,根据1∶1掷硬币原则把患者分为试验组54例与对照组54例。对照组给予琥珀酸铁溶液治疗,试验组给予多糖铁复合物胶囊治疗,比较两组临床疗效、血液生化指标及不良妊娠结局情况。结果:试验组总有效率高于对照组(P<0.05);两组治疗4周后平均红细胞体积与平均红细胞血红蛋白浓度高于治疗前,且试验组高于对照组(P<0.05);试验组剖宫产、胎膜早破、前置胎盘、羊水过少发生率低于对照组(P<0.05);试验组新生儿窒息、新生儿胆红素脑病、产后出血、产褥感染发生率低于对照组(P<0.05)。结论:多糖铁复合物胶囊治疗孕中晚期缺铁性贫血患者的治疗效果良好,可提高患者平均红细胞体积与平均红细胞血红蛋白浓度,降低剖宫产、胎膜早破、前置胎盘、羊水过少发生率,改善母婴预后。

Objective:To investigate the effect of iron polysaccharide complex capsule on patients with iron deficiency anemia in middle and late pregnancy.Methods:From October 2021 to June 2022,108 cases of puerpera with intermediate to late stage iron deficiency anemia who chose to build a file and deliver were selected as study subjects,and the patients were divided into experimental group(n=54)and control group(n=54)according to the principle of 1:1 coin toss.The control group was treated with iron succinate solution and the experimental group was treated with iron polysaccharide complex capsules,and the clinical efficacy,blood biochemical indexes and adverse pregnancy outcomes of the two groups were compared.Results:The total effective rate of the experimental group was higher than that of the control group(P<0.05).After 4 weeks of treatment,the mean corpuscular volume and mean corpuscular hemoglobin concentration in the two groups were higher than those before treatment,and those in the experimental group were higher than the control group(P<0.05).The incidence of cesarean section,premature rupture of membranes,placenta previa and amniotic fluid in the experimental group was lower than that in the control group(P<0.05).The incidence of neonatal asphyxia,neonatal bilirubin encephalopathy,postpartum hemorrhage and puerperal infection in the experimental group was lower than that in the control group(P<0.05).Conclusion:Iron polysaccharide complex capsules are effective in treating patients with iron deficiency anemia in mid to late pregnancy,increasing the mean red blood cell volume and mean red blood cell hemoglobin concentration of patients,reducing the incidence of cesarean delivery,premature rupture of membranes,placenta praevia,and amniotic fluid,and improving the prognosis of mothers and infants.